Science & Enterprise subscription

Follow us on Twitter

  • A new company developing treatments to relieve allergic reactions with reprogrammed antibodies began work and is ra… https://t.co/LFNVxych8d
    about 59 mins ago
  • New post on Science and Enterprise: New Allergy Biotech Launches, Raises $10M https://t.co/x5W0TwnCBu #Science #Business
    about 1 hour ago
  • Two companies and NIH are beginning a clinical trial of synthetic antibodies to both treat and prevent Covid-19 inf… https://t.co/LaUrUiRmhk
    about 20 hours ago
  • New post on Science and Enterprise: Trial Set for Covid-19 Antibodies in Long-Term Care https://t.co/tF0a7CDgGr #Science #Business
    about 20 hours ago
  • The numbers of vaccine candidates in development and clinical trials show modest but steady growth, now up to 157 a… https://t.co/AO2DxxTgF8
    about 1 day ago

Please share Science & Enterprise

Pharma, Biotech Ink Deal on Anti-Inflammatory Candidate

Euro Notes and Coins (U.S. Mint)

(U.S. Mint)

XOMA Ltd., a biotechnology company in Berkeley, California, and Les Laboratoires Servier a French pharmaceutical company, announced an agreement to develop and commercialize XOMA 052, XOMA’s anti-inflammatory drug candidate. XOMA 052 is designed to inhibit the pro-inflammatory cytokine interleukin-1 beta believed to be a primary trigger of pathologic inflammation in multiple diseases.

Under the agreement, XOMA will receive $35 million upfront, as well as up to $470 million in milestone payments and tiered royalties of about 15 percent. XOMA will retain development and commercialization rights for Behcet’s uveitis and other inflammatory and oncology conditions in the U.S. and Japan. Servier receives similar rights in the rest of the world.

Servier will fund the first $50 million of XOMA 052 development expenses and half of further expenses for the Behcet’s uveitis conditon. XOMA 052 is expected to advance into a Phase 3 trial in Behcet’s uveitis in 2011. The deal also involves funding, licensing, and commercialization rights for diabetes and cardiovascular disease conditions.

*     *     *

1 comment to Pharma, Biotech Ink Deal on Anti-Inflammatory Candidate